Knoxville GLP-1 Weight Loss FAQ

Semaglutide (GLP-1 agonist; Ozempic, Wegovy) and tirzepatide (dual GIP/GLP-1 agonist; Mounjaro, Zepbound). Both reduce appetite and intake via satiety signaling; tirzepatide's additional receptor is associated with larger average weight loss. Selection is individualized.

Initiation at semaglutide 0.25 mg weekly or tirzepatide 2.5 mg weekly, with gradual escalation as tolerated. Rapid escalation precipitates gastrointestinal adverse events, so titration is paced and managed at monthly review.

BMI of 30 or greater, or 27 or greater with a weight-related comorbidity such as dysglycemia, hypertension, or sleep apnea, in an adult with a documented regain history. No fixed minimum, but a genuine indication is required and confirmed before initiation.

Laboratory work (commonly a metabolic panel, with A1c and lipids as indicated) at baseline and interval per clinical judgment, plus monthly physician review governing dose adjustment. Continuity of the supervising physician is a documented adherence factor.

Mean reductions of 15-20% of body weight by approximately month six, contingent on dose escalation toward an effective level. The trajectory is non-linear and an early plateau is expected as adaptive mechanisms engage.

Absolute: pregnancy, lactation, personal or family history of medullary thyroid carcinoma or MEN-2. Relative: active pancreatitis, significant biliary disease, severe GI disorders, specific drug interactions. Minimal indication or eating-disorder history redirects to alternative management.